A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age

NCT05903183 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
264
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Icosavax, Inc.